Msd Sub Merck Company Profile

✉ Email this page to a colleague

MSD SUB MERCK has fourteen approved drugs.

There are twenty US patents protecting MSD SUB MERCK drugs.

There are five hundred and forty-nine patent family members on MSD SUB MERCK drugs in sixty countries and one hundred and fifty-eight supplementary protection certificates in nineteen countries.

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Msd Sub Merck	ISENTRESS	raltegravir potassium	POWDER;ORAL	205786-001	Dec 20, 2013		RX	Yes	Yes	7,169,780*PED	⤷ Sign Up				⤷ Sign Up
Msd Sub Merck	STEGLUJAN	ertugliflozin; sitagliptin phosphate	TABLET;ORAL	209805-002	Dec 19, 2017		RX	Yes	Yes		⤷ Sign Up				⤷ Sign Up
Msd Sub Merck	JANUMET	metformin hydrochloride; sitagliptin phosphate	TABLET;ORAL	022044-001	Mar 30, 2007		RX	Yes	No	7,326,708*PED	⤷ Sign Up			Y	⤷ Sign Up
Msd Sub Merck	JANUMET	metformin hydrochloride; sitagliptin phosphate	TABLET;ORAL	022044-002	Mar 30, 2007		RX	Yes	Yes		⤷ Sign Up				⤷ Sign Up
Msd Sub Merck	SEGLUROMET	ertugliflozin; metformin hydrochloride	TABLET;ORAL	209806-001	Dec 19, 2017		RX	Yes	No		⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Msd Sub Merck	STEGLUJAN	ertugliflozin; sitagliptin phosphate	TABLET;ORAL	209805-002	Dec 19, 2017	7,459,428	⤷ Sign Up
Msd Sub Merck	INTEGRILIN	eptifibatide	INJECTABLE;INJECTION	020718-001	May 18, 1998	5,807,825	⤷ Sign Up
Msd Sub Merck	ISENTRESS	raltegravir potassium	POWDER;ORAL	205786-001	Dec 20, 2013	7,217,713*PED	⤷ Sign Up
Msd Sub Merck	STEGLUJAN	ertugliflozin; sitagliptin phosphate	TABLET;ORAL	209805-002	Dec 19, 2017	7,078,381	⤷ Sign Up
Msd Sub Merck	ISENTRESS	raltegravir potassium	TABLET, CHEWABLE;ORAL	203045-001	Dec 21, 2011	7,169,780*PED	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Injection	2 mg/mL, 100 mL vial	➤ Subscribe	2008-12-18
➤ Subscribe	Injection	1 g/vial	➤ Subscribe	2013-06-20
➤ Subscribe	Ophthalmic Solution	2%	➤ Subscribe	2005-10-11
➤ Subscribe	Extended-release Tablets	100 mg/1000 mg	➤ Subscribe	2012-10-22
➤ Subscribe	Injection	2 mg/mL, 10 mL vial	➤ Subscribe	2008-09-30
➤ Subscribe	Injection	0.75 mg/mL, 100 mL vial	➤ Subscribe	2009-06-05
➤ Subscribe	Tablets	400 mg	➤ Subscribe	2011-10-12
➤ Subscribe	Extended-release Capsules	50 mg/500 mg and 50 mg/1000 mg	➤ Subscribe	2012-03-16
➤ Subscribe	Tablets	50 mg/500 mg and 50 mg/1000 mg	➤ Subscribe	2010-10-18

Subscribe to access the full database, or Sign Up
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2334687	2018/028	Ireland	⤷ Sign Up	PRODUCT NAME: ERTUGLIFLOZIN, OPTIONALLY AS A CRYSTAL FORM, PARTICULARLY AS A CO-CRYSTAL WITH L-PYROGLUTAMIC ACID, AND SPECIFICALLY AS ERTUGLIFLOZIN L-PYROGLUTAMIC ACID; REGISTRATION NO/DATE: EU/1/18/1267/001 EU/1/18/1267/012 20180321
2410844	680	Finland	⤷ Sign Up
1441735	91428	Luxembourg	⤷ Sign Up	PRODUCT NAME: RALTEGRAVIR (ISENTRESS ); AUTHORISATION NUMBER AND DATE: EU/1/07/436/01 20080102
2410844	C20160050	Estonia	⤷ Sign Up	(93) SZ 65861 01, 01.04.2016 (93) CH 65861 01, 01.04.2016
2498758	CR 2020 00017	Denmark	⤷ Sign Up	PRODUCT NAME: METFORMIN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; SAXAGLIPTIN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; DAPAGLIFLOZIN ELLER ET FARMACEUTISK ACCEPTABELT SOLVAT DERAF; REG. NO/DATE: EU/1/19/1401 20191113
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.